A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT02776527
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib Mesylate Tablets — DRUG
    taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses

Study Details

The main purpose of this study is to evaluate whether the Apatinib can improve the disease free survival (DFS) of gastric cancer patients in stage IIIB/IIIc, who had completed postoprative adjuvant chemotherapy. Meanwhile, the investigators also will evaluate whether the Apatinib can improve the overall survival (OS), estimate the quality of life of patients have taken the Apatinib and monitor the security of Apatinib.

Key Dates

Start date
Apr 30, 2016
Status verified
Apr 2016
Primary completion
Apr 30, 2017
Completion
Apr 30, 2017

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A group
    D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
  • No Intervention: B group
    D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox

Primary Outcome Measure

disease free survival [ Time Frame: 2 years ]

Central Contacts

Related Studies